Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR

Deutsche Bank AG purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 134,258 shares of the company's stock, valued at approximately $1,368,000. Deutsche Bank AG owned 0.08% of Vir Biotechnology at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in VIR. Pictet Asset Management Holding SA boosted its holdings in Vir Biotechnology by 10,878.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company's stock worth $13,268,000 after purchasing an additional 1,467,340 shares during the period. Candriam S.C.A. raised its holdings in shares of Vir Biotechnology by 10.1% during the first quarter. Candriam S.C.A. now owns 1,135,763 shares of the company's stock worth $10,176,000 after purchasing an additional 104,100 shares during the period. UBS Group AG raised its holdings in shares of Vir Biotechnology by 94.6% during the fourth quarter. UBS Group AG now owns 417,965 shares of the company's stock worth $2,520,000 after purchasing an additional 203,203 shares during the period. Avidity Partners Management LP bought a new position in shares of Vir Biotechnology in the 1st quarter worth about $8,512,000. Finally, OP Asset Management Ltd bought a new position in shares of Vir Biotechnology in the 1st quarter worth about $1,013,000. Institutional investors and hedge funds own 65.32% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Vir Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research report on Thursday, August 6th. Leerink Partners upped their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Finally, HC Wainwright reiterated a "buy" rating on shares of Vir Biotechnology in a research report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $21.57.

Insider Buying and Selling

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the transaction, the director directly owned 21,216 shares of the company's stock, valued at $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by corporate insiders.

Vir Biotechnology Trading Down 4.2%

NASDAQ VIR opened at $10.83 on Friday. The stock's 50-day moving average price is $9.59 and its two-hundred day moving average price is $9.30. The company has a market cap of $1.83 billion, a PE ratio of -5.82 and a beta of 1.66. Vir Biotechnology, Inc. has a 1 year low of $4.75 and a 1 year high of $11.66.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The company's revenue was up 19582.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.80) EPS. Research analysts forecast that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source